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Neurocognitive impairment is one the non-infectious
comorbidities related to HIV infection [1]. An increasing
number of studies have shown the importance of asses-
sing attention, motor, memory and cognitive functions
under standardized conditions [2]. We have designed a
computerized assessment tool, adapting some well-known
methods of neurocognitive evaluation, and we have
initiated a pilot study to assess the neurocognitive status
of HIV-positive patients and controls.
We assessed patients by applying the Motor Screening
Task (MST: providing data on the sensorimotor function
or comprehension), the Finger Tapping Test (FTT: motor
function, self-directed manual motor speed), the Symbol
Digit Test (SDT: divided attention, visual scanning, track-
ing and motor speed), and the Stroop Task (ST: selective
attention and cognitive flexibility). All subjects were eval-
uated with this computerized set of tests during an
appointment with the clinical psychologist. For statistical
assessment, the T score was used.
We assessed 10 HIV-positive patients and 15 controls.
The median age and standard deviation were 26.5±11.5
years (range: 23-54) in the HIV group and 34±8 years
(range: 25-53) in the control group. The MST scores
were 720±131 ms and 629±79 ms in HIV vs. controls.
The FTT scores were 167±24 ms and 163±12 ms in
HIV vs. controls. The SDT scores were 6646±2905 ms
and 2994±681 ms in HIV vs. controls. The ST scores were
689±92 ms, 1602±1009 ms and 2045±580 ms in the HIV
group and 486±118 ms, 1041±244 ms and 1023±163 ms
in the control group. Despite the low number of subjects
included in the study, the T score showed a statistically
significant difference between the two groups for MST,
SDT, ST; no statistically significant difference was
observed for FTT between the two groups.
This pilot study has shown that in HIV-positive
patients, the cognitive deficit tends to appear earlier than
the motor one. Larger studies are needed to confirm
these preliminary results and to provide more informa-
tion on the clinical impact of this computerized tool for
neurocognitive screening.
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